Literature DB >> 7674250

Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection.

F Lioté1, E Pertuiset, B Cochand-Priollet, M F D'Agay, H Dombret, P Numéric, G D'Anglejan, D Kuntz.   

Abstract

A 57-year-old woman receiving low dose methotrexate (MTX) for rheumatoid arthritis (RA) developed a B lymphoproliferative disease (LPD) that was initially considered as large cell non-Hodgkin's lymphoma of B cell phenotype. Epstein-Barr virus (EBV) cytotoxic latent membrane protein-1 (LMP-1) expression was found in some large cells. The lymphoproliferative disease reversed with MTX discontinuation and without chemotherapy. These EBV-associated LPD in patients with RA receiving MTX or other immunosuppressive agents seem to be similar to those triggered by EBV in transplant patients receiving cyclosporine A. MTX withdrawal and short followup should be considered before chemotherapy since spontaneous regression is possible.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674250

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

Review 2.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 3.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate.

Authors:  C Bologna; M C Picot; C Jorgensen; P Viu; R Verdier; J Sany
Journal:  Ann Rheum Dis       Date:  1997-02       Impact factor: 19.103

5.  Epstein-Barr virus-associated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate.

Authors:  Yuko Hirose; Yasufumi Masaki; Jun Okada; Chang Gi Kim; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

6.  Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis.

Authors:  Lindsey Tilling; Sue Townsend; Joel David
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Cutaneous methotrexate-related T-cell lymphoproliferative disorder with CD4, CD30, CD56, EBV-positive tumor cell infiltration: a case illustration and a brief review.

Authors:  Issei Omori; Ruriko Kawanabe; Yuki Hashimoto; Aya Mitsui; Kako Kodama; Shinichi Nogi; Hirotaka Tsuno; Ayako Horita; Ikuo Saito; Hanako Ohmatsu
Journal:  Am J Blood Res       Date:  2021-04-15

Review 8.  Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature.

Authors:  Rita Rizzi; Paola Curci; Mario Delia; Erminia Rinaldi; Antonia Chiefa; Giorgina Specchia; Vincenzo Liso
Journal:  Med Oncol       Date:  2008-05-07       Impact factor: 3.064

Review 9.  Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review.

Authors:  Sachiko Furukawa; Kazunari Oobu; Masafumi Moriyama; Shintaro Kawano; Saori Sako; Jun-Nosuke Hayashida; Ryota Matsubara; Ken-Ichi Ogata; Tamotsu Kiyoshima; Seiji Nakamura
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

10.  Morbidity of solid cancer in Behςet's disease: analysis of 11 cases in a series of 506 patients.

Authors:  So Young Na; Jaeyoung Shin; Eun-So Lee
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.